Alignment Healthcare Inc Dossier - Source-backed chat

Alignment Healthcare Inc

ALHCNASDAQ

SectorHealth Care

IndustryHealthcare Plans

Beta (adjusted)1.07

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $8.16Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $1.7B

Enterprise Value $1.3B

Shares Outstanding 210.8M diluted

Next Earnings Date29 Oct 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Alignment Healthcare is a high-growth, technology-enabled Medicare Advantage pure-play that is successfully scaling its consumer-centric model. Powered by its proprietary AVA technology platform and Care Anywhere clinical model, the company is demonstrating strong operating leverage, rapid membership growth, and a clear path to sustainable profitability. The surprisingly favorable 2027 Medicare Advantage rate update announced by CMS in April 2026 provides a significant tailwind, reducing industry-wide premium compression risks and positioning Alignment to capture market share as larger peers pull back benefits.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets13 analysts · as of 18 Aug 2026

Low · most bearish analyst$16.00

Mean target$24.08

High · most bullish analyst$30.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$16.0020%

Elevated outpatient utilization and specialty drug costs pressure the MBR, offsetting top-line growth. Regulatory changes or risk-adjustment model transitions (such as the final phase of V28 in 2026) compress premium yields more than anticipated, delaying the company's timeline to GAAP net income profitability.

Base CaseCentral scenario

$24.0850%

Matches the consensus mean

Alignment executes in line with its raised FY 2026 guidance, achieving revenue of $5.16B to $5.20B and Adjusted EBITDA of $138M to $163M. Membership scales steadily toward ~295,000, and the company maintains disciplined medical cost management with an MBR around 88.0%, supported by its AVA platform's automated claims adjudication and predictive analytics.

Bull CaseUpside scenario

$30.0030%

Alignment accelerates membership growth beyond guidance, leveraging its superior Star ratings (100% of members in plans rated 4+ Stars) to capture market share from legacy insurers. Cohort margins mature faster than expected, driving the Medical Benefits Ratio (MBR) down toward the low-80s for mature cohorts, resulting in significant Adjusted EBITDA outperformance.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Industry-leading organic membership growth (+31% YoY in Q1 2026) driven by strong sales and high member retention.
Proprietary AVA technology platform enables superior care coordination, predictive risk scoring, and over 60% claims auto-adjudication.
Favorable regulatory tailwinds from the CMS 2027 Medicare Advantage rate update, which provides an effective ~5% rate increase.
Refinanced capital structure following the convertible notes issuance, reducing interest expenses and strengthening liquidity.

Key Investment Risks

Exposure to medical cost volatility and unexpected utilization spikes among the polychronic senior population.
Regulatory risks associated with Medicare Advantage risk-adjustment models (V28 phase-in) and potential changes to Star rating methodologies.
Geographic concentration, with a significant portion of membership and revenue generated in the California market.

Thesis Invalidation Triggers

A material drop in Medicare Advantage Star ratings below the 4.0-star threshold, which would eliminate quality bonus payments.
MBR consistently exceeding 89.5% due to unmanaged medical cost inflation, indicating a failure of the Care Anywhere clinical model.
Significant deceleration in membership growth below 15% YoY, signaling market saturation or loss of competitive advantage.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.